|
Dr. Axel Obermeier has nearly two decades of experience in science and industry.
He studied Biology at the Universities of Regensburg and Heidelberg,
supported by a scholarship from the "Studienstiftung des deutschen
Volkes".
For
his pioneering work on the epidermal and nerve growth factor receptors
during his Ph.D. in the laboratory of Prof. Axel Ullrich (Max Planck
Institute for Biochemistry) he was awarded the Adolf Butenandt
fellowship.
After his PhD, he has worked three years for Glaxo at the Institute of Molecular & Cell Biology (IMCB) in Singapore and the Institute of Neurology in London,
and four years as group leader cell biology with GPC Biotech AG,
Martinsried. He then joined Sireen AG, where he was responsible for
cell and molecular biology, assay development and knowledge management.
In the course of the merger between NADAG and Sireen to form Sirenade
Pharmaceuticals, Dr. Obermeier became Director of Biology, Pharmacology
and later Director of Research / acting CSO. He played a key role in
the company’s roadshow and M&A process.
From
1992 to 2008 Dr. Obermeier has authored 18 scientific papers in
high-ranking international peer-reviewed journals and several patents
and patent applications.
As
a result he combines a broad scientific and technical expertise with
managerial experience including project management, outsourcing,
licensing, pharma/biotech collaborations and M&A.
Prior
to founding his own consulting company in August 2007, Dr. Obermeier
has been working as a Senior Consultant with Bioscience Valuation GmbH
for roughly two years. In this function he executed and led several
mandates for international (European, U.S., Australian) pharma and
biotech companies comprising: R&D portfolio analysis including
strategic support with project re-prioritization and portfolio
restructuring; generation of quantitative pipeline models; quantitative
analysis and benchmarking of success rates, timelines, resource/FTE
allocation and expenditures; market research (primary and desk);
detailed scientific analysis and financial valuation of R&D
projects (expected net present value (eNPV)) in the context of
licensing, fund raising and M&A activities; and compilation of
macroeconomic financial models for the improvement of the U.S.
healthcare system. Project target indications included oncology,
inflammation and respiratory, gastroenterology, pain, arthritis, opiate
addiction, and animal health (antibiotics).
Since
founding of AOLSC in August 2007 he has been working for big pharma as
well as biotech / life science companies and investor firms in the
area of business
development and R&D dealing with small molecules, biologics
and stem cell therapeutics. Mandates included financial (eNPV)
evaluations of R&D projects (therapeutics, diagnostics and
devices), IP analyses, competitor analyses, primary and desk market
research, scientific literature and R&D investigations, support
with business
plans and grant applications, strategic advice, identifying customers
and establishing partnerships and collaborations.
His expertise is further extended through a network of collaborations
with other renowned companies and experts in the fields of consulting,
regulatory aspects, investment banking and capital markets,
intellectual property and patent law, public relations, controlling,
and human resources.
|
